Durable and treatment-agnostic muc16 expression in ovarian cancer supports targeted antibody-drug conjugate development
IGCS 2026
Kathleen Moore, Lauren Dockery, R. Naumann, David O'Malley, Michelle Rowland, Dayana Delgado, Lennart Langouche, Kathleen Keegan, David Lennon, Ashwini Pai, Dhiren Patel, Robert Coleman
Introduction
Mucin 16 (MUC16), a cell-surface glycoprotein involved in tumor
cell proliferation, metastasis, and immune evasion, is overexpressed in ∼80%
of epithelial ovarian cancers (OC). Previous analyses showed that MUC16
expression is higher than other ADC targets in OC, and remains stable irrespective of platinum-sensitivity status. This study aimed to assess MUC16
expression, and that of other ADC targets, before and after standard-of-care
treatments in OC.
Methods
RNA-sequencing data from a de-identified real-world database
(Tempus AI, Inc.) were used to examine MUC16 expression in pre- and posttreatment OC samples (3.0% matched). Median MUC16 expression was
quantified as log2(TPM+1).
Results
The analysis included 8,267 OC samples. Median MUC16 expression
remained high before and after standard-of-care treatments, including platinum/non-platinum chemotherapy, bevacizumab with/without platinum, and
PARP inhibitors, with consistently small effect sizes (Figure 1). Other ADC
targets (TROP2, FRα, and CLDN6) showed more variable treatment-associated
expression than MUC16 across standard-of-care therapies (Figure 2).
Conclusion/Implications
MUC16 expression is highly stable over time across
standard-of-care therapies for OC, with lower treatment-associated variability
than other ADC targets, indicating low susceptibility to therapy-induced
modulation. As MUC16 is not downregulated by standard-of-care treatments,
MUC16-directed ADCs may be suitable for use both in combination with
standard early-line platinum-based treatment and in the relapsed setting.
HWK-016, a next-generation ADC targeting the non-shed extracellular domain
of MUC16, is currently being evaluated in a phase 1 clinical trial
(NCT07470853) in patients with advanced/metastatic solid tumors, including
OC. Future analyses aim to identify variables independently associated with
MUC16 expression in matched patient samples.
Related publications